Popular Filters
Trials for Dilated Cardiomyopathy Patients
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Behavioural Intervention
Biomarker-Guided Intervention for Chemotherapy Toxicity in Cancer Patients
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial will test whether a biomarker-guided cardioprotection strategy using NTproBNP is safe and feasible for breast cancer and lymphoma patients treated with anthracyclines, as compared to usual care.
AT-001 for Diabetic Cardiomyopathy
Recruiting1 awardPhase 3
Beverly Hills, California
This trial is testing a new drug called AT-001 to see if it can help adults with a heart condition related to diabetes. The goal is to improve their heart function or prevent it from getting worse, especially for those at high risk of severe heart failure.
Mesenchymal Stem Cell Therapy
Mesenchymal Stem Cell Transplantation for Heart Failure
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the side effects of donor bone marrow derived mesenchymal stem cells in patients with cardiomyopathy caused by anthracyclines. The cells may help to control symptoms of heart failure and improve heart function.
Trials for Heart Failure Patients
Behavioural Intervention
Biomarker-Guided Intervention for Chemotherapy Toxicity in Cancer Patients
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial will test whether a biomarker-guided cardioprotection strategy using NTproBNP is safe and feasible for breast cancer and lymphoma patients treated with anthracyclines, as compared to usual care.
Mesenchymal Stem Cell Therapy
Mesenchymal Stem Cell Transplantation for Heart Failure
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the side effects of donor bone marrow derived mesenchymal stem cells in patients with cardiomyopathy caused by anthracyclines. The cells may help to control symptoms of heart failure and improve heart function.
Phase 3 Trials
AT-001 for Diabetic Cardiomyopathy
Recruiting1 awardPhase 3
Beverly Hills, California
This trial is testing a new drug called AT-001 to see if it can help adults with a heart condition related to diabetes. The goal is to improve their heart function or prevent it from getting worse, especially for those at high risk of severe heart failure.
Patisiran for Cardiomyopathy
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing a medication called patisiran. It aims to help people with a heart condition caused by abnormal protein buildup. The medication works by lowering the levels of these harmful proteins in the body. Patisiran has been shown to significantly reduce symptoms and improve quality of life in patients.
Trials With No Placebo
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Antisense Oligonucleotide
ION-682884 for Transthyretin Amyloid Cardiomyopathy
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial involves injecting a special medicine under the skin to reduce a harmful protein in older patients with heart issues due to abnormal protein deposits. The medicine works by lowering the levels of a protein that can damage the heart.
Behavioural Intervention
Biomarker-Guided Intervention for Chemotherapy Toxicity in Cancer Patients
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial will test whether a biomarker-guided cardioprotection strategy using NTproBNP is safe and feasible for breast cancer and lymphoma patients treated with anthracyclines, as compared to usual care.
Mesenchymal Stem Cell Therapy
Mesenchymal Stem Cell Transplantation for Heart Failure
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the side effects of donor bone marrow derived mesenchymal stem cells in patients with cardiomyopathy caused by anthracyclines. The cells may help to control symptoms of heart failure and improve heart function.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.